Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, has announced the completion of its oversubscribed Series C equity financing raising EUR 67.5m (USD 72m) from a syndicate
Tags :Vischer
LASCCO, a biomedical-technology company, and Abionic, a nanotechnology company, both based at the Biopôle of Lausanne, entered into a licensing agreement with Fapon Biotech, a global leading life sciences company, based in Dongguan (China)
Memo Therapeutics, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF 25 million series C financing round led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group,
In a strategic move to enhance its presence in the healthcare sector, Swiss Post, under the legal guidance of Vischer, has acquired a stake in Steriparc, a promising joint venture specializing in the externalized handling
Vischer acted as legal advisor to LimmaTech Biologics as it successfully concluded a USD 37 million (CHF 33 million) Series A financing round, co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund.
Vischer acted as legal counsel to Afinum in its investment in Hofstetter PCB, the European provider of printed circuit boards plating and special final finishing services. Together with its prior investment in GS Swiss, Afinum
Epiterna, a Swiss longevity company founded in 2022 by Alejandro Ocampo and Kevin Perez as a spin-off from Alejandro Ocampo’s laboratory at the University of Lausanne, has raised EUR 10 million from Prima Materia, an investment
Luciole Medical, a Swiss medical technology company specialized in brain monitoring, acquires Spiegelberg & Co., an established medical device company and provider of highly specialized devices and consumables for neurosurgery, from SHS Capital. Spiegelberg has
RELIEF THERAPEUTICS Holding has entered into has entered into a definitive agreement for the sale and purchase in a private placement of 1.5m Relief shares and warrants to purchase up to 1.5m Relief shares. The
Oculis Holding, a global biopharmaceutical company purposefully driven to save sight and improve eye care, has placed a follow-on public offering of 3.5m ordinary shares at a public offering price of USD 11.50 per ordinary share,
